NCT07522151

Clinical Study of Adebrelimab Therapy in the Perioperative Treatment of Gastric Cancer or Gastroesophageal Junction Cancer

A Randomized, Double-blind, Multicenter Phase III Trial of Adebrelimab (SHR-1316) Plus S-1 and Oxaliplatin (SOX) Versus Placebo Plus S-1 and Oxaliplatin in the Perioperative Treatment of Resectable Gastric or Gastroesophageal Junction Cancer

• Status: Not Yet Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 874 (estimated)
• Sponsor: Shanghai Shengdi Pharmaceutical Co., Ltd · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This study was a randomized, double-blind, multi-center phase III clinical trial to evaluate the event-free survival (EFS) of Adebrelimab with S-1 and oxaliplatin versus placebo combined with S-1 and oxaliplatin, and to evaluate the efficacy, safety and tolerability of the two combination regimens.

Conditions

• Locally Advanced Gastric or Gastroesophageal Junction Cancer

Interventions

Type	Name	Description
DRUG	Adebrelimab plus S-1 and oxaliplatin	Adebrelimab plus S-1 and oxaliplatin
DRUG	Adebrelimab blank preparation plus S-1 and oxaliplatin.	Adebrelimab blank preparation plus S-1 and oxaliplatin.

Timeline

• Start date: 2026-05-01
• Primary completion: 2029-12-01
• Completion: 2034-02-01
• First posted: 2026-04-13
• Last updated: 2026-04-13

Locations

1 site across 1 country: China